ArticleAccounts of chemical research2025
Mass Spectrometry-Based Protein Footprinting for Protein Structure Characterization.
Article in Accounts of chemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Optimized Digestion Conditions for Membrane Protein Footprinting and Mass Spectrometry Analysis.Membranes · 2026Article
- Capturing Early Aggregation Transitions of Disordered Tau by Covalent Footprinting Mass Spectrometry.Analytical chemistry · 2026Article
- Assessment of Protein Conformation via Diazirine-Promoted Oxidation of Methionine and Tryptophan Residues.Analytical chemistry · 2026Article
- Screening pertactin-specific antibodies and evaluating competitive epitope recognition by native mass spectrometry.Chemical science · 2026Article
- A New Detailed Mass Offset Search in MSFragger for Improved Interpretation of Complex PTMs.Journal of proteome research · 2026Article
- Metalloprotein-Based Nanomedicines: Design Strategies, Functional Mechanisms, and Biomedical Applications.International journal of molecular sciences · 2026Review
- Mass spectrometry footprinting reveals how kinetic stabilizers counteract transthyretin dynamics altered by pathogenic mutations.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- State-of-the-Art and Future Directions in Structural Proteomics.Molecular & cellular proteomics : MCP · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Protein higher-order structure (HOS) is key to biological function because the mechanisms of protein machinery are encoded in protein three-dimensional structures. Mass spectrometry (MS)-based protein footprinting is advancing protein structure characterization by mapping solvent-accessible regions of proteins and changes in H-bonding, thereby providing higher order structural information. Footprinting provides insights into protein dynamics, conformational changes, and interactions, and when conducted in a differential way, can readily reveal those regions that undergo conformational change in response to perturbations such as ligand binding, mutation, thermal stress, or aggregation. Building on firsthand experience in developing and applying protein footprinting, we provide an account of our progress in method development and applications.In the development section, we describe fast footprinting with reactive reagents (free radicals, carbenes, carbocations) with emphasis on fast photochemical oxidation of proteins (FPOP). The rates of the modifying reactions are usually faster than protein folding/unfolding, ensuring that the chemistry captures the change without biasing the structural information. We then describe slow, specific side-chain labeling or slow footprinting and hydrogen-deuterium exchange (HDX) to provide context for fast footprinting and to show that, with validation, these modifications can deliver valid structural information. One advantage of slow footprinting is that usually no special apparatus (e.g., laser, synchrotron) is needed. We acknowledge that no single footprint is sufficient, and complementary approaches are needed for structure comparisons.In the second part, we cover several of our footprinting applications for the study of biotherapeutics, metal-bound proteins, aggregating (amyloid) proteins, and integral membrane proteins (IMPs). Solving structural problems in these four areas is often challenging for other high-resolution approaches, motivating the development of protein footprinting as a complementary approach. For example, obtaining structural data for the bound and unbound forms of a protein requires that both forms are amenable for 3D structure determination. For problems of this type, information on changes in structure often provides an answer. For amyloid proteins, structures of the starting state (monomer) and the final fibril state are obtainable by standard methods, but the important structures causing disease appear to be those of soluble oligomers that are beyond high-resolution approaches because the mix of structures is polydisperse in number and size. Moreover, the relevant structures are those that occur in cell or in vivo, not in vitro, ruling out many current methods that are not up to the demands of working in complex milieu. IMPs are another appropriate target because they are unstable in water (in the absence of membranes, detergents) and may not retain their HOS during the long signal averaging needed for standard tools. Furthermore, the structural changes occurring in membrane transport or induced by drug binding or other interactions, for example, resist high resolution determination.We provide here an account on MS-based footprinting, broadly describing its multifaceted development, applications, and challenges based on our first-hand experience in fast and slow footprinting and in HDX. The Account is intended for investigators contemplating the use of these tools. We hope to catalyze refinements in methods and applications through collaborative, cross-disciplinary research that involves organic and analytical chemists, material scientists, and structural biologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.